|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online 13 May 2008
doi: 10.1242/jcs.028019
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research Article |


1 King's College London, The Randall Division for Cell and Molecular Biophysics, and Cardiovascular Division, New Hunt's House, London SE1 1UL, UK
2 The Folkhälsan Institute of Genetics and Department of Medical Genetics, University of Helsinki, Biomedicum, Helsinki, Finland
3 INSERM, U582, Institut de Myologie, Paris, France
4 Université Pierre et Marie Curie, Paris, France
5 Department of Neurology, Vasa Central Hospital, Vasa, Finland
¶ Author for correspondence (e-mail: mathias.gautel{at}kcl.ac.uk)
Accepted 11 March 2008
| Summary |
|---|
|
|
|---|
Key words: M-band, Limb-girdle muscular dystrophy, Myomesin, Obscurin, Titin
| Introduction |
|---|
|
|
|---|
Obscurin is a recently identified sarcomeric giant protein participating in myofibril organization by forming homotypic interactions between immunoglobulin (Ig)-like domains of the Z-disk portion of titin and Ig-domains near the C-terminus of obscurin (Young et al., 2001
). Despite the fact that obscurin was first identified as a binding partner of the titin Z-disk region, the dominant subsarcomeric location of obscurin epitopes in mature myofibrils and cultured cardiomyocytes is the M-band (Bagnato et al., 2003
; Borisov et al., 2003
; Young et al., 2001
); this is also where the nematode analogue of obscurin, UNC-89, is localized (Ferrara et al., 2005
). The obscurin gene is differentially spliced in a manner that is complex and, as yet, incompletely understood (Fukuzawa et al., 2005
; Russell et al., 2002
). The A-isoforms of obscurin contain a C-terminal sequence that binds to the small M-band-localized ankyrin isoforms ankyrin 1.5 and ankyrin 1.9. On the basis of these results, one of the potential roles of obscurin has been suggested to be the tethering of sarcoplasmic reticulum (SR) and contractile apparatus (Armani et al., 2006
; Bagnato et al., 2003
; Kontrogianni-Konstantopoulos et al., 2003
). Although the molecular basis for the differential localization of obscurin to both Z-disks and M-bands is, so far, unclear, the possibility that multiple alternatively spliced variants can be generated from its gene, which is assembled from over 80 exons encoding mostly single domains (Fukuzawa et al., 2005
; Russell et al., 2002
), might offer an explanation.
Interestingly, the M-band portion of titin at its extreme C-terminus has emerged as a hotspot for autosomal dominant and recessive mutations, causing at least three distinct human myopathies. At present, three different mutations have been reported in Mex6 (exon 363 of the titin gene), which encodes the last Ig domain (M10). Heterozygous mutations co-segregate with tibial muscular dystrophy patients [TMD; Mendelian Inheritance in Man (MIM)600334], an autosomal dominant late-onset distal myopathy. The more-severe childhood-onset Limb-girdle muscular dystrophy 2J (LGMD2J; MIM608807) phenotype was found to be homozygous for the Finnish TMD founder mutation FINmaj (Udd et al., 2005
). The mutations published so far are: (1) a unique 11-bp deletion/insertion at position 293,269-293,279 of the titin gene (FINmaj) that was found to lead to the exchange of four sequential amino acids in M10 in Finnish patients [Glu to Val, Val to Lys, Thr to Glu and Trp to Lys (Hackman et al., 2002
)]; (2) a point mutation at position 293,357 that was found to lead to the exchange of Leu to Pro in French patients (Hackman et al., 2002
); (3) a point mutation at position 293,329 that was found to lead to the exchange of Ile to Asn in Belgian patients (Van den Bergh et al., 2003
). These myopathy-associated mutations of titin M10 suggest the importance of this domain for maintaining functional myofibrils. Recently, an autosomal recessive cardiac and skeletal titin myopathy with two different C-terminal titin deletions encompassing M10 was described (Carmignac et al., 2007
), which is also known as Salih congenital muscular dystrophy (Salih et al., 1998
; Subahi, 2001
).
In this study, we unravel the interactions between the main structural sarcomeric M-band components titin and myomesin with the N-terminal part of obscurin and with a novel protein with similar domain structure to the N-terminal part of obscurin, called obscurin-like 1 (Obsl1). The interaction between titin and obscurin/Obsl1 is decreased or abolished by mutations in titin M10 that are linked to muscular diseases, leading to the disordered association of obscurin/Obsl1 with myofibrils. These results indicate that the incorporation of obscurin/Obsl1 into the sarcomeric M-band is important for myofibril maintenance.
| Results |
|---|
|
|
|---|
|
Several overlapping fragments were generated to map the interaction between myomesin and Obsl1 more precisely. Obsl1 constructs containing domain Ig3 were able to bind myomesin both in Y2H and pulldown assays (Fig. 2A,B). Similarly, the binding site for Obsl1 on myomesin was mapped to the linker region between domains My4 and My5 (Fig. 2A). Because of the homology of sequence and domain pattern between Obsl1 and obscurin, we tested whether also domain 3 of obscurin (Ob-Ig3) could bind the same region in myomesin. Ob-Ig3 interacted in the same way as Obsl1, suggesting that the homology of both proteins also reflects functional homology of their interaction capacity (Fig. 2A,B).
|
Titin M10 interacts with the N-terminus of obscurin and Obsl1 – titin, obscurin and myomesin can form a ternary complex
To corroborate the interaction results in a parallel approach, we searched for ligands of the N-terminal region of obscurin or Obsl1 in Y2H screens. Using Ig-domains 1-5 of obscurin as bait, five HIS3- and β-galactosidase-positive clones were identified from a human cardiac cDNA library and were analyzed by sequencing. Two of these contained identical inserts derived from the N-terminal part of myomesin, comprising the linker region between My4 and My5. This result is in excellent agreement with the interaction we identified independently for obscurin and Obsl1 using the myomesin bait.
The remaining three clones all encoded the most C-terminal part of titin. The smallest clone delimited the minimum binding site on titin to the insertion Is7 and the C-terminal Ig-domain M10 of titin. In order to further narrow down the minimum binding sites on both titin and obscurin, a series of truncation constructs were analyzed for binding in forced Y2H assays. As shown in Fig. 3A, only constructs containing titin M10, but not those containing only Is7, showed binding to obscurin, whereas obscurin Ob-Ig1 was sufficient for titin M10 binding. The binding between titin M10 and obscurin Ig1 was confirmed by GST pulldown assays (Fig. 3B).
|
The arrangement of titin- and myomesin-binding sites on successive, individual domains on obscurin suggests that they might function independently. To test this hypothesis, we analyzed the ability of obscurin fragments to bind to titin and myomesin simultaneously. Myomesin My4-My5 did not show appreciable binding to titin M10 (Fig. 3C). In the presence of My4-My5, obscurin Ig1-Ig2 bound to titin M10, with no binding of the myomesin fragment. However, when this experiment was carried out with obscurin Ig1-Ig3, a fragment encompassing both the titin- and myomesin-binding sites, both obscurin and myomesin My4-My5 were found in the titin-bound fraction, demonstrating that obscurin can target myomesin to titin M10 (Fig. 3C). These results also demonstrate that the interaction of titin and myomesin with obscurin are mutually independent, and that the obscurin and Obsl1 N-termini can function as a crosslinker between titin and myomesin.
Overexpression of the minimal binding sites in obscurin, myomesin or titin disrupts endogenous obscurin localization
Would disruption of either the titin or myomesin interaction therefore lead to altered sarcomeric localization of obscurin? We addressed this important question in NRCs that were transfected with Ob-Ig1 (the binding site for titin), or Ob-Ig3 (the binding site for myomesin) fused to GFP. In Ob-Ig1-transfected cells (Fig. 4), the staining of anti-obscurin antibodies (here anti-Ob58-59) at the M-band was weakened compared with non-transfected cells (Fig. 4) or Ob-Ig2-transfected cells (not shown). Quantitative image analysis showed that the apparent ratio of obscurin to titin was reduced from about 2:1 down to 1:1. In contrast to endogenous obscurin, the intensity and location of the T51 antibody epitope in the M9 Ig domain of titin (Obermann et al., 1996
) close to M10 was not changed by exogenous Ob-Ig1 overexpression (Fig. 4). Similarly, this dominant-negative effect on endogenous obscurin was also observed for Obsl1-Ig1- and titin-M10-transfected cells (Fig. 4).
|
|
The dominant-negative effects of transfected obscurin fragments in cultured cardiomyocytes firmly support the concept that obscurin is incorporated into the M-band via the interactions of Ob-Ig1 and Ob-Ig3 with titin and myomesin.
Intriguingly, no changes in the correct localization of either titin or myomesin at the microscopic level were observed after transfection of any constructs that affect the correct localization of obscurin to the sarcomeric M-band. This suggests that obscurin localization depends on both myomesin and M-band titin, but not vice versa.
siRNA-mediated knockdown of myomesin results in an aberrant localization of obscurin and unordered sarcomeres
Because myomesin seemed to be a major determinant for the correct integration of obscurin into the sarcomere, we investigated whether the reduction of endogenous myomesin would also affect obscurin localization, comparable to the overexpression of the minimal binding sites. By transfecting a myomesin siRNA vector into NRCs, we achieved strong perturbation of the endogenous myomesin pattern (Fig. 6). The remaining myomesin largely failed to assemble into ordered M-band stripes, probably because disruption of the structural links between myomesin and myosin, titin or obscurin leads to a general failure in the coordinated assembly of the M-band. The localization of obscurin in siRNA-transfected cells was also generally cytoplasmic and lacked an ordered sarcomeric striation pattern (Fig. 6). Occasional weak association with myomesin in rudimentary stripes could be observed (Fig. 6, inset). Considering the results of overexpression experiments, it appears, therefore, that both titin and myomesin interactions are required to target obscurin, and probably Obsl1, to the M-band.
|
Myopathy mutations in titin M10 abolish its ability to bind obscurin, and disrupt M-band-bound obscurin
Because obscurin and Obsl1 are presently the only known sarcomeric interaction partners for the C-terminal Ig-domain M10 of titin, we were interested to see whether the disease-associated mutations in titin M10 affect its binding to obscurin.
To clarify this issue, a forced Y2H assay was performed that compared the binding of obscurin to the Ig-domain M10 of titin, with all published titin Mex6 (exon 363) mutations from human muscular dystrophy patients being mimicked (Fig. 7A). As expected, wild-type M10 showed growth on selective media and β-galactosidase activation. By contrast, M10 containing the Finnish or French TMD mutations did not show either reporter gene activation, indicating absent or strongly weakened interaction. Unlike the Finnish and French mutations, the Belgian TMD mutation showed positive reporter gene activities, similar to wild type. The effects of TMD and/or LGDM2J mutations on obscurin binding were confirmed by a GST pulldown assay (Fig. 7B). In agreement with the forced Y2H results, Ob-Ig1 showed robust binding to both wild-type M10 and the Belgian TMD mutation, but not to the Finnish or French mutant M10. Despite completely negative Y2H responses for the French and Finnish mutations, very weak binding of Obsl1-Ig1 to these mutant forms of M10 could be observed. Attempts to quantify the interaction strength of the mutant domains by biosensor assays were thwarted by very low-affinity, non-saturable binding. Whether this apparent residual, very weak interaction is functionally sufficient to maintain the M-band functions of Obsl1 will require further structural and biophysical analysis.
|
We therefore wanted to investigate the location of obscurin and Obsl1 in biopsies of LGMD2J (titin Mex6, exon 363, Finnish homozygous) as well as Salih myopathy (titin Mex3 deletion, exon 360) patients. It was previously confirmed in muscle biopsies from these myopathies that the M8-M9 titin epitope was lost completely, whereas the nearby A169-A170 titin epitopes were normally localized to the M-band, as was myomesin (Carmignac et al., 2007
; Hackman et al., 2002
). We therefore stained the limited available cryosections of affected, as well as control, muscles for obscurin and myomesin. In the affected muscles, obscurin lost its sharply defined M-band localization in LGMD2J Mex6-mutant M-bands and was severely mislocalized in Salih myopathy Mex3-mutant M-bands. This was observed even in areas in which M-band structure labelled by anti-myomesin antibodies appeared normal; obscurin also did not relocalize to the binding site at the Z-disk (Fig. 7C).
| Discussion |
|---|
|
|
|---|
Obscurin and obscurin-like 1
The giant modular protein obscurin was first identified in Y2H screens with Z-disk portions of titin (Young et al., 2001
). Surprisingly, however, adult muscles show obscurin at the sarcomeric M-band with only occasional weaker Z-disk staining. This suggests a second sarcomeric binding site responsible for M-band targeting. The interactions of the obscurin N-terminus with titin M10 and myomesin, two well-characterized M-band components, now establish this `missing link'. It furthermore lends strong support for a transverse orientation of obscurin with respect to the sarcomeric filament axis, with the N-terminus being myofibril-bound and the ankyrin-binding C-terminus most probably being associated with the SR enveloping the sarcomere. We also identified a new interaction of myomesin and titin with Obsl1, a smaller modular protein with patterns of Ig and fibronectin (Fn)3-like domains highly similar to the N-terminal part of obscurin. Homologous domains in Obsl1 interacted with titin and myomesin. Obsl1 lacks the ankyrin-binding non-modular region found in obscurin-A and also, unlike obscurin-A and obscurin-B, contains no signalling domains. The major function of this new protein might therefore be structural, possibly adding an additional layer of crosslinks between myosin filaments. During the preparation of this manuscript, Obsl1 was described as a protein of the M-band, Z-disk, intercalated disk, nuclear lamina and cytosol (Geisler et al., 2007
). The antibodies purified for this study, however, show marked M-band localization, which is only disrupted by the dominant-negative effects of myomesin, titin or the binding domains to these on Obsl1 itself (supplementary material Fig. S2). We also found that the N-terminus of Obsl1 contains five instead of four Ig domains, which would be in agreement with the highly homologous domain structure in the N-terminus of obscurin (Fig. 1). Furthermore, we identified novel splice variants of Obsl1 that lack the N-terminal domains responsible for titin and myomesin interaction. It is possible, therefore, that the puzzlingly complex picture of Obsl1 localization observed by Geisler et al. (Geisler et al., 2007
) relates to those isoforms lacking the M-band-targeting domains 1-3.
Previous siRNA knockdown experiments of obscurin suggested that obscurin might be necessary for the lateral alignment of myofibrils and for sarcomere assembly (Kontrogianni-Konstantopoulos et al., 2006
). However, the total loss of M-band-bound obscurin upon transfection of My4-My5, with completely preserved myofibril structure and lateral alignment even after prolonged culture of these cardiomyocytes (Fig. 5A), suggests that the phenotype of a total knockdown of obscurin is not explained by crosslinking myofibrils at the M-band. Rather, because siRNA knockdown will abolish the entire molecule, including the SR-linking C-terminus and the C-terminal GEF and kinase domains, it seems possible that the knockdown of obscurin signalling functions and/or SR anchorage might be responsible for the observed siRNA phenotypes. Intriguingly, competing obscurin out of the M-band does not lead to its association with the Z-disk, suggesting that Z-disk and M-band sorting might not be competitive processes but regulated on another level, possibly by alternative splicing or posttranslational modifications.
Myomesin
Our analyses show that myomesin plays a far more complex role in M-band formation than previously expected. Apart from being a crosslinker of myosin filaments and an anchor of titin, it is also crucially involved in targeting obscurin and Obsl1 to the M-band. Our siRNA knockdown experiments furthermore suggest that the presence of M-band titin and obscurin alone is insufficient for M-band formation in the absence of myomesin, leading to total destruction of not only the M-band but of overall myofibril structure. This phenotype is reminiscent of the homozygous ablation of M-band titin in embryonic stem (ES)-cell derived cardiomyocytes (Musa et al., 2006
), underscoring the importance of the interdependent network of M-band proteins for structural stability.
The human and mouse genomes contain three myomesin genes (MYOM1, MYOM2 and MYOM3). Only the product of MYOM1, myomesin, was able to bind to obscurin/Obsl1. The expression of myomesin (MYOM1) and M-protein (MYOM2) is fibre-type specific, with M-protein being expressed predominantly in fast fibres of the mouse (Agarkova et al., 2003
). Varying stoichiometry of titin and myosin to the MYOM family members could thus lead to fibre-type-specific differences in the stability of the ternary complex of titin, myomesin proteins and obscurin/Obsl1.
Titin
Our data show for the first time in detail how the extreme C-terminus of titin is involved in protein-protein interactions with structural M-band proteins. The ternary complex between the first three Ig domains of obscurin, the interdomain linker between My4 and My5 of myomesin, and titin M10 places all three proteins in a spatially strictly confined context that is limited by the 4-nm dimensions of the Ig domains. Previously, dot-blot analysis had indicated an interaction between titin M4 and myomesin domains My4 and My6, which might be regulated by myomesin phosphorylation (Obermann et al., 1997
). We therefore verified this interaction by two independent methods, Y2H analysis and pulldown assays. In both assays, we could not confirm the titin-M4–myomesin interaction. Furthermore, contrary to the transfection of titin M10, Ob-Ig1 or Ob-Ig3 and the homologous domains in Obsl1, transfection of titin M4 had no effect on M-band localization of myomesin (data not shown). We conclude that this interaction is unlikely to be physiologically significant for static M-band structure but cannot rule out that it might be transiently involved during M-band assembly. Interestingly, the interaction of myomesin and obscurin Ig3 in the same region is not dependent on phosphorylation, suggesting that it is static rather than dynamic. Together with previous ultrastructural and interaction data, our data therefore provide new spatial constraints for modelling the M-band (Fig. 8). Titin and myomesin domains have previously been localized by immuno-electron microscopy (Obermann et al., 1996
). Because the size of the primary and secondary antibody complexes used as label in this study is large (ca 30 nm) compared with the size of the M-band, and epitope access in the tight myofibril lattice is spatially limited, leading to possible errors in defining the epitope as the centre of mass, these domain positions may be considered as guidelines rather than absolute measures. We have therefore based our revised M-band model on the positional constraints posed by the protein interactions defined here and on the general orientation of titin and myomesin revealed by electron microscopy.
|
In contrast to this partial failure of sarcomere maintenance, the total homozygous ablation of M-band titin, including M8 to M10, leads to a complete disruption of primary myofibrillogenesis in targeted ES-cell-derived cardiomyocytes (Musa et al., 2006
), with diffuse localization of obscurin and myomesin. Comparison of the two phenotypes suggests that crucial interactions allowing minimal M-band formation must reside in titin domains M8 to M10. The interactions of M10 with obscurin and Obsl1 seem to contribute to M-band stability, although M-bands are at least temporarily stable when obscurin is completely diffuse (see Fig. 5A). The different phenotypes of the two genetic titin-M-band-deletion models could thus be explained by residual M10 interactions in the internal deletion model, linking the remaining M-band titin fragment to myomesin via obscurin/Obsl1.
Implications for hereditary myopathies
A number of human titin M-band mutations have recently been identified that cause autosomal recessive or dominant myopathies. Among them, tibial muscular dystrophy and LGMD2J are caused by mutations in the titin domain M10 (Udd et al., 2005
). Clinical severity correlates to the expected biochemical effects of the mutations. The Finnish and French mutations disrupt key structural features of the M10 Ig-fold and are clinically characterized as more severe compared with the Belgian TMD mutation, which is a structurally less-severe missense mutation in the β-barrel. The clinically more-severe mutations reduce titin-obscurin/Obsl1 binding severely, whereas binding by the Belgian TMD mutation is not detectably reduced [although small differences in the diffusion coefficient (Kd) would escape our assays and might still be pathomechanistically significant]. Interestingly, the biochemical findings are reflected by the absence of M-band-localized/mislocalized obscurin in LGMD2J homozygous muscle samples despite preserved M-band structure and normal lateral alignment of myofibrils. These observations suggest that loss of M-band obscurin has no immediate consequences on sarcomere stability and myofibril order, or on their lateral alignment in humans. Defects in the precise spatial arrangement of excitation-contraction coupling could also explain the phenotype of the aforementioned siRNA and morpholino experiments (Raeker et al., 2006
).
A new group of severe, autosomal recessive titinopathies was recently identified, in which premature stop codons in titin exons Mex1 and Mex3 (exons 358 and 360) cause deletions of the C-terminal part of M-band titin, encompassing domains M5 to M10 and M8 to M10, respectively (Carmignac et al., 2007
). Although the affected region in these mutations encompasses further binding sites, such as that for calpain-3, the presence of a cardiac phenotype suggests that loss of obscurin/Obsl1 is likely to be involved (because calpain-3 is not expressed in heart muscle).
In summary, we have identified the M-band-targeting mechanism for the giant multicompartment protein obscurin and its smaller homologue Obsl1. These findings are of relevance for several hereditary human myopathies involving loss of this binding site on titin. In addition, these observations provide crucial insight into the molecular interactions relevant for M-band assembly and provide physical constraints relevant for structural models of the M-band.
| Materials and Methods |
|---|
|
|
|---|
RNAi constructs
The RNAi vector H1-GFP-cDNA3.1-Zeo was derived from inserting the coding sequence of EGFP (Clontech) into pcDNA3.1-Zeo (Invitrogen), enabling detection for transfected cells by fluorescence, and insertion of the H1-promotor RNAi cassette of the pSuper vector [(Brummelkamp et al., 2002
), kind gift of R. Agami, The Netherlands Cancer Institute, Amsterdam, The Netherlands] into GFP-pcDNA3.1-Zeo. RNAi constructs for myomesin were generated by linker ligation into H1-GFP-cDNA3.1-Zeo using the following oligos: Myom, 5'-GATCCCCtatggctcggagaccagcgTTCAAGAGAcgctggtctccgagccataTTTTTGGAAA-3' and Myom, 3'-AGCTTTTCCAAAAAtatggctcggagaccagcgTCTCTTGAAcgctggtctccgagccataGGG-5' (lowercase nucleotides indicate the homologous complementary sequences of the hairpin). The sequence and correct integration was verified by sequencing. Co-transfections of the siRNA construct with HA-labelled myomesin and M-protein constructs in COS cells confirmed the specificity to myomesin.
Mutagenesis
Site-directed mutagenesis was carried out using a modified version of the QuikChange protocol (Stratagene). All nucleotide numbers corresponded to NM003319/GenBank [Homo sapiens titin (TTN), transcript variant N2-B]. Mutated nucleotides are shown in capitals. (1) Finnish mutation primer: 5'-gggtgagcctaccccagTGAAAGAAAAAtcctgtggtggaagaaaaatcc-3', 80791-80840. (2) French mutation primer: 5'-cagatgacctgacaacccCgatcatcatggacgtacagaaac-3', 80877-80918. (3) Belgian mutation primer: 5'-agaacaggggaggttccacaAtgaaaacacagatgacctgac-3', 80848-80889. The sequence and correct integration were verified by sequencing. Titin exons are based on the complete titin gene, TTN (Homo sapiens titin; GeneID: 7273, HGNC:12403).
GST pulldown assay
GST pulldown assays were essentially performed as described (Lange et al., 2002
). Cos1 cells transfected with pEGFP-fusion constructs were extracted with IP buffer [10 mM Tris-HCl (pH 7.9), 150 mM NaCl, 0.5% NP-40, 1 mM DTT supplemented with a protease inhibitor cocktail (Roche)] and the cell lysates were incubated with certain amounts of beads coupled with GST fusion proteins for 2 hours on ice. Following incubation, beads were washed four times in IP buffer. The proteins retained on the beads were separated on SDS-PAGE and then transferred onto nitrocellulose membrane following standard procedures. Blots were treated with mouse monoclonal anti-GFP (Roche) and subsequently with a secondary antibody [HRP-conjugated anti-mouse (DAKO Cytomation, Glostrup, Denmark)]. Detection was performed by ECL western blotting analysis system following the manufacturer's manual [Amersham (GE Healthcare)].
Cell culture and transfection
NRCs were isolated from rats and cultured essentially as described (Lange et al., 2002
). NRC was transfected with pEGFP-fusion constructs using Escort III (Sigma-Aldrich) following the manufacturer's manual. After changing medium to NRC maintenance medium (78% DMEM, 19.4% Medium M199, 4% horse serum, 1% penicillin/streptomycin, 4 mM glutamine, 0.1 mM phenylephrine), cells were cultured for another 48 hours to promote the expression.
Immunostaining
Cryosections were fixed with pre-chilled acetone for 5 minutes at –20°C. NRCs were fixed with 4% paraformaldehyde in PBS for 6 minutes, then neutralized with 0.1 M Glycine in PBS and permeabilized with 0.2% Triton X-100 in PBS. After washing with PBS, the sample was blocked with 5% normal goat serum/1% BSA in GB [20 mM Tris-HCl (pH 7.5), 155 mM NaCl, 2 mM EGTA, 2 mM MgCl2] for 30 minutes. The sample was incubated with primary antibody in 1% BSA/GB for 1 hour and, after washing with PBS, was incubated with secondary antibody in 1% BSA/GB for 1 hour. Following sufficient washing with PBS, the sample was mounted in mounting medium [30 mM Tris-HCl (pH 9.5), 70% Glycerol, 5% n-propyl gallate]. All processes were performed at room temperature except for acetone fixation.
Antibodies
Three antibodies used as primary antibodies for immunostaining are described below. T51: mouse monoclonal antibody raised against titin M9 Ig domain (Obermann et al., 1996
); Myomesin B4: mouse monoclonal antibody raised against myomesin domain My12 (Grove et al., 1984
); Ob58-59 [former Ob48-49, re-named after genomic analysis (Fukuzawa et al., 2005
)]: rabbit polyclonal antibody raised against two Ig domains; Ob58 (exOb48) and Ob59 (exOb49) (Young et al., 2001
). A rabbit polyclonal antibody was raised against recombinant Obsl1-Ig1 and affinity purified against the antigen as described (Harlow and Lane, 1988
). All fluorescent-conjugated secondary antibodies were purchased from Jackson ImmunoResearch (USA).
Confocal microscopy and image analysis
Cell preparations and tissue sections were imaged with a Zeiss LSM510 confocal microscope in sequential scanning mode, using a 63x oil-immersion objective and instrument zoom rates between 1x and 2.5x.
Ratiometry
To see whether GFP-X expression affected blue protein expression, images were imported into Mathematica 5.2 for ratiometric analysis. Briefly, each channel of a 24-bit RGB image was filtered with a 3x3 boxed mean filter to dampen noise. The blue channel was then normalized by division with the red channel. Noise-dependent division artefacts were suppressed by converting very low intensity red pixels (<10% of dynamic range) into large values (100x dynamic range). The green channel containing the GFP signal was then extracted and thresholded to obtain a mask that covered the whole GFP-X-expressing cell(s). This enabled automatic extraction of two subsets of pixels from the red-normalized blue channel, those coincident with the GFP mask, and the rest lying outside of this mask. A histogram of normalized values for each subset was then created from which the weighted mean normalized intensity values were calculated for the GFP-positive subset and the GFP-negative subset. The ratio of these two values (GFP-positive:GFP-negative) was then calculated. This value indicated whether expression of GFP-fusion proteins increased or decreased blue protein levels (increased and decreased ratio respectively).
| Acknowledgments |
|---|
| Footnotes |
|---|
* These authors contributed equally to this work ![]()
Current address: Department of Medicine, University of California San Diego, USA ![]()
Current address: Department of Experimental Medical Science, Lund University, Sweden ![]()
| References |
|---|
|
|
|---|
Agarkova, I. and Perriard, J. C. (2005). The M-band: an elastic web that crosslinks thick filaments in the center of the sarcomere. Trends Cell Biol. 15, 477-485.[CrossRef][Medline]
Agarkova, I., Ehler, E., Lange, S., Schoenauer, R. and Perriard, J. C. (2003). M-band: a safeguard for sarcomere stability? J. Muscle Res. Cell Motil. 24, 191-203.[CrossRef][Medline]
Agarkova, I., Schoenauer, R., Ehler, E., Carlsson, L., Carlsson, E., Thornell, L. E. and Perriard, J. C. (2004). The molecular composition of the sarcomeric M-band correlates with muscle fiber type. Eur. J. Cell Biol. 83, 193-204.[CrossRef][Medline]
Agarkova, I., Schoenauer, R., Perriard, J. C. and Lange, S. (2006). Addition to myomesin's family: expression and properties of novel sarcomeric M-band component, myom3. J. Muscle Res. Cell Motil. 27, 507.
Armani, A., Galli, S., Giacomello, E., Bagnato, P., Barone, V., Rossi, D. and Sorrentino, V. (2006). Molecular interactions with obscurin are involved in the localization of muscle-specific small ankyrin1 isoforms to subcompartments of the sarcoplasmic reticulum. Exp. Cell Res. 312, 3546-3558.[CrossRef][Medline]
Bagnato, P., Barone, V., Giacomello, E., Rossi, D. and Sorrentino, V. (2003). Binding of an ankyrin-1 isoform to obscurin suggests a molecular link between the sarcoplasmic reticulum and myofibrils in striated muscles. J. Cell Biol. 160, 245-253.
Borisov, A. B., Raeker, M. O., Kontrogianni-Konstantopoulos, A., Yang, K., Kurnit, D. M., Bloch, R. J. and Russell, M. W. (2003). Rapid response of cardiac obscurin gene cluster to aortic stenosis: differential activation of Rho-GEF and MLCK and involvement in hypertrophic growth. Biochem. Biophys. Res. Commun. 310, 910-918.[CrossRef][Medline]
Brummelkamp, T. R., Bernards, R. and Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553.
Carmignac, V., Salih, M. A. M., Quijano-Roy, S., Marchand, S., Al Rayess, M. M., Mukhtar, M. M., Urtizberea, J. A., Labeit, S., Guicheney, P., Leturcq, F. et al. (2007). C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann. Neurol. 61, 340-351.[CrossRef][Medline]
Ferrara, T. M., Flaherty, D. B. and Benian, G. M. (2005). Titin/connectin-related proteins in C. elegans: a review and new findings. J. Muscle Res. Cell Motil. 26, 435-447.[CrossRef][Medline]
Fukuzawa, A., Idowu, S. and Gautel, M. (2005). Complete human gene structure of obscurin: implications for isoform generation by differential splicing. J. Muscle Res. Cell Motil. 26, 427-434.[CrossRef][Medline]
Geisler, S. B., Robinson, D., Hauringa, M., Raeker, M. O., Borisov, A. B., Westfall, M. V. and Russell, M. W. (2007). Obscurin-like 1, OBSL1, is a novel cytoskeletal protein related to obscurin. Genomics 4, 521-531.
Gotthardt, M., Hammer, R. E., Hubner, N., Monti, J., Witt, C. C., McNabb, M., Richardson, J. A., Granzier, H., Labeit, S. and Herz, J. (2002). Conditional expression of mutant M-line titins results in cardiomyopathy with altered sarcomere structure. J. Biol. Chem. 278, 6059-6065.[Medline]
Grove, B. K., Kurer, V., Lehner, C., Doetschman, T. C., Perriard, J. C. and Eppenberger, H. M. (1984). A new 185,000-dalton skeletal muscle protein detected by monoclonal antibodies. J. Cell Biol. 98, 518-524.
Hackman, P., Vihola, A., Haravuori, H., Marchand, S., Sarparanta, J., De Seze, J., Labeit, S., Witt, C., Peltonen, L., Richard, I. et al. (2002). Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am. J. Hum. Genet. 71, 492-500.[CrossRef][Medline]
Harlow, E. and Lane, D. (1988). Antibodies, A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
Hoshijima, M. (2006). Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures. Am. J. Physiol. Heart Circ. Physiol. 290, H1313-H1325.
Kontrogianni-Konstantopoulos, A., Jones, E. M., Van Rossum, D. B. and Bloch, R. J. (2003). Obscurin is a ligand for small ankyrin 1 in skeletal muscle. Mol. Biol. Cell 14, 1138-1148.
Kontrogianni-Konstantopoulos, A., Catino, D. H., Strong, J. C., Sutter, S., Borisov, A. B., Pumplin, D. W., Russell, M. W. and Bloch, R. J. (2006). Obscurin modulates the assembly and organization of sarcomeres and the sarcoplasmic reticulum. FASEB J. 20, 2102-2111.
Lange, S., Auerbach, D., McLoughlin, P., Perriard, E., Schafer, B. W., Perriard, J. C. and Ehler, E. (2002). Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. J. Cell Sci. 115, 4925-4936.[CrossRef][Medline]
Lange, S., Ehler, E. and Gautel, M. (2006). From A to Z and back? Multicompartment proteins in the sarcomere. Trends Cell Biol. 16, 11-18.[CrossRef][Medline]
Linke, W. A. (2008). Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc. Res. 77, 637-648.
Musa, H., Meek, S., Gautel, M., Peddie, D., Smith, A. J. H. and Peckham, M. (2006). Targeted homozygous deletion of M-band titin in cardiomyocytes prevents sarcomere formation. J. Cell Sci. 119, 4322-4331.
Obermann, W. M. J., Gautel, M., Steiner, F., Van der Ven, P., Weber, K. and Fürst, D. O. (1996). The structure of the sarcomeric M band: localization of defined domains of myomesin, M-protein and the 250 kD carboxy-terminal region of titin by immunoelectron microscopy. J. Cell Biol. 134, 1441-1453.
Obermann, W. M. J., Gautel, M., Weber, K. and Fürst, D. O. (1997). Molecular structure of the sarcomeric M band: mapping of titin- and myosin-binding domains in myomesin and the identification of a potential regulatory phosphorylation site in myomesin. EMBO J. 16, 211-220.[CrossRef][Medline]
Peng, J., Raddatz, K., Labeit, S., Granzier, H. and Gotthardt, M. (2006). Muscle atrophy in titin M-line deficient mice. J. Muscle Res. Cell Motil. 26, 381-388.[CrossRef]
Peng, J., Raddatz, K., Molkentin, J. D., Wu, Y., Labeit, S., Granzier, H. and Gotthardt, M. (2007). Cardiac hypertrophy and reduced contractility in hearts deficient in the titin kinase region. Circulation 115, 743-751.
Raeker, M. O., Su, F., Geisler, S. B., Borisov, A. B., Kontrogianni-Konstantopoulos, A., Lyons, S. E. and Russell, M. W. (2006). Obscurin is required for the lateral alignment of striated myofibrils in zebrafish. Dev. Dyn. 235, 2018-2029.[CrossRef][Medline]
Russell, M. W., Raeker, M. O., Korytkowski, K. A. and Sonneman, K. J. (2002). Identification, tissue expression and chromosomal localization of human Obscurin-MLCK, a member of the titin and Dbl families of myosin light chain kinases. Gene 282, 237-246.[CrossRef][Medline]
Salih, M. A., Al Rayess, M., Cutshall, S., Urtizberea, J. A., Al-Turaiki, M. H., Ozo, C. O., Straub, V., Akbar, M., Abid, M., Andeejani, A. et al. (1998). A novel form of familial congenital muscular dystrophy in two adolescents. Neuropediatrics 29, 289-293.[CrossRef][Medline]
Schoenauer, R., Lange, S., Hirschy, A., Ehler, E., Perriard, J. C. and Agarkova, I. (2008). Myomesin 3, a novel structural component of the M-band in striated muscle. J. Mol. Biol. 376, 338-351.[CrossRef][Medline]
Subahi, S. A. (2001). Distinguishing cardiac features of a novel form of congenital muscular dystrophy (Salih cmd). Pediatr. Cardiol. 22, 297-301.[Medline]
Tskhovrebova, L. and Trinick, J. (2003). Titin: properties and family relationships. Nat. Rev. Mol. Cell Biol. 4, 679-689.[CrossRef][Medline]
Udd, B., Vihola, A., Sarparanta, J., Richard, I. and Hackman, P. (2005). Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology 64, 636-642.
Van den Bergh, P. Y., Bouquiaux, O., Verellen, C., Marchand, S., Richard, I., Hackman, P. and Udd, B. (2003). Tibial muscular dystrophy in a Belgian family. Ann. Neurol. 54, 248-251.[CrossRef][Medline]
Young, P., Ferguson, C., Banuelos, S. and Gautel, M. (1998). Molecular structure of the sarcomeric Z-disk: two types of titin interactions lead to an asymmetrical sorting of alpha-actinin. EMBO J. 17, 1614-1624.[CrossRef][Medline]
Young, P., Ehler, E. and Gautel, M. (2001). Obscurin, a giant sarcomeric Rho guanine nucleotide exchange factor protein involved in sarcomere assembly. J. Cell Biol. 154, 123-136.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
Related articles in JCS:
This article has been cited by other articles:
![]() |
A. Kontrogianni-Konstantopoulos, M. A. Ackermann, A. L. Bowman, S. V. Yap, and R. J. Bloch Muscle Giants: Molecular Scaffolds in Sarcomerogenesis Physiol Rev, October 1, 2009; 89(4): 1217 - 1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Ford-Speelman, J. A. Roche, A. L. Bowman, and R. J. Bloch The Rho-Guanine Nucleotide Exchange Factor Domain of Obscurin Activates RhoA Signaling in Skeletal Muscle Mol. Biol. Cell, September 1, 2009; 20(17): 3905 - 3917. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lange, K. Ouyang, G. Meyer, L. Cui, H. Cheng, R. L. Lieber, and J. Chen Obscurin determines the architecture of the longitudinal sarcoplasmic reticulum J. Cell Sci., August 1, 2009; 122(15): 2640 - 2650. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Ackermann, L.-Y. R. Hu, A. L. Bowman, R. J. Bloch, and A. Kontrogianni-Konstantopoulos Obscurin Interacts with a Novel Isoform of MyBP-C Slow at the Periphery of the Sarcomeric M-Band and Regulates Thick Filament Assembly Mol. Biol. Cell, June 15, 2009; 20(12): 2963 - 2978. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Coisy-Quivy, O. Touzet, A. Bourret, R. A. Hipskind, J. Mercier, P. Fort, and A. Philips TC10 controls human myofibril organization and is activated by the sarcomeric RhoGEF obscurin J. Cell Sci., April 1, 2009; 122(7): 947 - 956. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Cusimano, F. Pampinella, E. Giacomello, and V. Sorrentino Assembly and dynamics of proteins of the longitudinal and junctional sarcoplasmic reticulum in skeletal muscle cells PNAS, March 24, 2009; 106(12): 4695 - 4700. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Puchner, A. Alexandrovich, A. L. Kho, U. Hensen, L. V. Schafer, B. Brandmeier, F. Grater, H. Grubmuller, H. E. Gaub, and M. Gautel Mechanoenzymatics of titin kinase PNAS, September 9, 2008; 105(36): 13385 - 13390. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||